drugset / Trial / NCT06085976

Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

NCT06085976

RandomizedParallel-groupDouble-blindPrevention

Summary

The goal of this double-blind clinical trial is to compare the efficacy of octreotide versus placebo in laparoscopic hepatectomy surgery in patients diagnosed with resectable hepatocarcinoma or liver metastases. The main questions it aims to answer are: * Decrease in intraoperative bleeding measured in ml of blood lost. * Decrease in the need for blood transfusion and use of intraoperative vasoactive drugs. Participants will receive octreotide or placebo after signing the informed consent form.

Timeline

Start
2023-08-14
Primary completion
2025-08-14
Completion
2025-11-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 25 ug Intravenous